News

Stefan Ameres, group leader at IMBA- Institute of Molecular Biotechnology of the Austrian Academy of Sciences- could secure a prestigious ERC...

Read more

Valneva announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB). Dr. Stanley A. Plotkin, MD and Dr. Anna...

Read more

Valneva announced today that its management team including Thomas Lingelbach, CEO, David Lawrence, CFO, and Franck Grimaud, CBO, will hold media,...

Read more

The highly collaborative environment of the Vienna BioCenter is once again demonstrated by three new Special Research Programmes (SFBs) going to...

Read more

On December 2nd, a large-scale public event, organized by the City of Vienna in cooperation with the Vienna BioCenter took place in the Globe Theater....

Read more

Multidrug resistance (MDR) is a fundamentally important medical phenomenon that undermines anticancer and anti-infective therapy of cancer or...

Read more

Valneva announced that the European Medicines Agency (EMA) has approved the extension of the shelf life of its Japanese encephalitis vaccine IXIARO® f...

Read more

Researchers in Vienna from Ulrich Elling’s laboratory at IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences – in...

Read more

Successful collaboration of research and industrial members of Vienna BioCenter awarded by the Austrian Research Promotion Agency (FFG) in the form of...

Read more

The prize was awarded for Ares Genetics’ ARESupa –Universal Pathogenome Assay, a diagnostic toolfor personalized antibiotic resistance diagnostics...

Read more

New insights into the process of DNA-looping change our view of how the genome is organised within cells. The discoveries by IMP-researchers now...

Read more

Valneva announced excellent final Phase 1 results for its single-shot chikungunya vaccine candidate, VLA1553.

 

Read more

Read more